Goldman Sachs Group set a GBX 3,800 ($52.50) price target on AstraZeneca (LON:AZN) in a research report released on Monday. The firm currently has a sell rating on the biopharmaceutical company’s stock.

Several other analysts have also weighed in on AZN. Investec lifted their price objective on shares of AstraZeneca from GBX 4,900 ($67.70) to GBX 5,500 ($75.99) and gave the company a buy rating in a research note on Monday, November 6th. Shore Capital reiterated a hold rating on shares of AstraZeneca in a research note on Thursday, February 15th. UBS Group set a GBX 4,550 ($62.86) price objective on shares of AstraZeneca and gave the company a neutral rating in a research note on Tuesday, February 6th. JPMorgan Chase & Co. reiterated a neutral rating on shares of AstraZeneca in a research note on Wednesday, November 1st. Finally, Deutsche Bank reiterated a buy rating and issued a GBX 5,700 ($78.75) price objective on shares of AstraZeneca in a research note on Monday, February 5th. Four equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the company. AstraZeneca has a consensus rating of Hold and a consensus price target of GBX 5,211.65 ($72.00).

Shares of AstraZeneca (LON AZN) opened at GBX 4,791 ($66.19) on Monday. The firm has a market cap of $61,120.00 and a price-to-earnings ratio of 2,818.24. AstraZeneca has a one year low of GBX 4,260 ($58.86) and a one year high of GBX 5,520 ($76.26).

The firm also recently declared a dividend, which will be paid on Monday, March 19th. Investors of record on Thursday, February 15th will be given a GBX 133.60 ($1.85) dividend. The ex-dividend date of this dividend is Thursday, February 15th. This represents a yield of 2.8%. This is an increase from AstraZeneca’s previous dividend of $68.90.

In other AstraZeneca news, insider Philip A. J. Broadley purchased 415 shares of AstraZeneca stock in a transaction that occurred on Friday, February 2nd. The stock was acquired at an average price of GBX 4,846 ($66.95) per share, with a total value of £20,110.90 ($27,785.16).

WARNING: This piece was posted by TheOlympiaReport and is the property of of TheOlympiaReport. If you are viewing this piece on another site, it was copied illegally and republished in violation of U.S. & international copyright law. The correct version of this piece can be viewed at

About AstraZeneca

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Analyst Recommendations for AstraZeneca (LON:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with's FREE daily email newsletter.